Marc Machaalani, MD on MAdCAM-1 - Takeaways - MDSpire

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

Share

  • 1

    Circulating MAdCAM-1 levels are prognostic of clinical outcomes in metastatic renal cell carcinoma across three independent clinical trials.

  • 2

    MAdCAM-1 serves as a dynamic biomarker for tracking gut dysbiosis-driven immune dysregulation.

  • 3

    The MAdCAM-1 pathway could be explored as a therapeutic target for microbiota-directed interventions.

  • 4

    Improving outcomes in treatment-resistant renal cell carcinoma may involve targeting the MAdCAM-1 pathway.

  • 5

    Research presented by Marc Machaalani, MD, highlights the significance of MAdCAM-1 in kidney cancer prognosis and treatment.

Original Source(s)

Marc Machaalani, MD on MAdCAM-1

  • November 5, 2025

Related Content

Comprehensive analysis of fatty acid desaturase 3 in clear cell renal cell carcinoma: insights into tumor progression, immune microenvironment, and clinical outcomes

Correction: MRI-based habitat radiomics for predicting WHO/ISUP nuclear grade in clear cell renal cell carcinoma

Renal clear cell carcinoma with co-existing tumor thrombosis of renal vein and ureter: a case report and review of the literature